Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
JNJ-95566692 in B-Cell Non-Hodgkin Lymphoid Malignancies
NCT07308132Phase 1Recruiting
- Sponsor
- Janssen Pharmaceutical
- Start
- Jan 2026
- Primary completion
- Aug 2028
- Modality
- Antibody Conjugates, Trispecific Antibodies, T-cell Engagers
- Countries
- 5
01
Overview
Phase 1, open-label trial of JNJ-95566692 in non-Hodgkin lymphoma (NHL) (7 arms), sponsored by Janssen Pharmaceutical. Primary endpoints: Number of Participants with Adverse Events (AEs) And Serious Adverse Events (SAEs) by Severity and Number of Participants with Dose Limiting Toxicity (DLTs). Started Jan 2026; status: recruiting.
02
Drugs
JNJ-95566692
03
Conditions
non-Hodgkin lymphoma (NHL)
Beyond the preview
Go deeper on NCT07308132.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07308132.